Editor in Chief Dr KK Aggarwal, Padma Shri Awardee Dated:01 May,2020
To free up care spaces, Maharashtra wants asymptomatic patients to be home
MUMBAI: Following central guidelines, the state government has directed that all asymptomatic positive patients going to private hospitals should be stamped and sent away for home quarantine after proper counselling.
Its time to start de-locking: Seal 2 km of area around active and new cases and open areas with no new cases in the last 14 days
CMAAO Coronavirus Facts and Myth Buster 76
(With regular inputs from Dr Monica Vasudev)
Relieve Stress by Changing the Interpretation
Stress is the reaction of the body or the mind to the interpretation of a known situation. Stress management, therefore, involves either changing the situation, changing the interpretation or taming the body the yogic way in such a way that stress does not affect the body.
Video of The day
Health Sutras By Dr K K Aggarwal
Avoid routine visits to hospital
Healthcare News Monitor
Shares of Glenmark Pharmaceuticals Ltd rose almost 9% on Thursday after the Indian drugmaker got an approval to conduct clinical trials with antiviral drug favipiravir, seen as a potential treatment for COVID-19.Favipiravir, manufactured under the brand name Avigan by a unit of Japan's Fujifilm Holdings Corp and approved for use as an anti-flu drug in the Asian island country in 2014, has been effective, with no obvious side-effects, in helping coronavirus patients recover, a Chinese official told reporters at a news conference last month. "After having successfully developed the API and the formulations ... Glenmark is all geared to immediately begin clinical trials on favipiravir on COVID-19 patients in India," Sushrut Kulkarni, executive vice-president for Global R&D, Glenmark Pharmaceuticals, said in a statement https://reut.rs/2VNF43h. The Drug Controller General of India, the country's drug regulator, did not immediately respond to Reuters request for a comment. On Wednesday, another Indian pharmaceutical company, Strides Pharma Science Ltd, said it had developed and commercialized favipiravir antiviral tablets, and had applied to Indian drug authorities to start trials.
The Indian Express
The Council of Scientific and Industrial Research (CSIR) on Thursday announced that it has identified 25 drugs which can be repurposed to treat COVID-19 patients. While much-discussed drugs such as remdesivir (developed by Gilead Sciences and used to treat the Ebola virus) and Hydroxychloroquine (HCQ) already feature on the CSIR list, favipiravir, a broad spectrum inhibitor of viral RNA polymerase, has now emerged as of one of the most promising drugs, according to scientists at the Council. Drug repositioning is the process of redeveloping a compound for use in a different disease. Favipiravir was developed by Fujifilm Toyama Chemical Ltd, Japan, a subsidiary of Japan’s Fujifilm Corporation, and is an approved treatment for common influenza. The drug is marketed in Russia, China and Japan. Dr Geethavani Rayasam, senior principal scientist at CSIR, said, “From preliminary data, it has been seen that favipiravir seems to be effective in treating the COVID-19 virus. The drug is used to treat influenza and is already being used in Russia, China, Italy and Japan to treat the COVID-19 virus. It has shown promising results.” The Hyderabad-based CSIR-IICT has developed a convenient and cost-effective synthetic process for favipiravir, it was announced. Cipla will conduct the investigations before launch of this drug against COVID-19 in India. The pharma company approached regulatory authority DCGI for approval for favipiravir to be launched in India, and under ICMR, it will conduct a suitable limited trial before marketing the product as Ciplenza.
Covid-19: Bengaluru hospital introduces robots to screen people to protect doctors from being infected
India Today- Nolan Pinto
A Bengaluru-based hospital has decided to use advance technology to screen Covid-19 patients before they meet a human doctor. The development comes at a time when doctors, medics across the country have been infected with Covid-19 while screening patients, resulting in shutting of hospitals. At the Fortis Hospital in Bengaluru, Karnataka, robots will now do the initial screening work, which was earlier done by doctors. Mitra and Mitri robots screen people who came to the hospital for Covid-19 check-ups. Mitra robot's job is simple. It asks 5 questions -- your name to telephone number. It also takes the person's body temperature and asks if the person is suffering from fever. Thereafter, it will ask the person if he/she is patient. If it is satisfied with all the details, it will send the person to meet a human being at the reception. However, if the person has been suspected of Covid-19 complications, it will direct him/her to Mitri robot. The second robot screens for Covid-19 and flu-like symptoms, arranges a video call with the doctor and then issues a slip to the patient to visit doctor. Dr (Wing Commander) A Nagasubramaniam, Medical Director, Fortis Hospital, Bannerghatta Road said that the hospital has taken this step to ensure that health care workers are protected in the beginning itself.
The initial symptoms of novel coronavirus disease were identified as Influenza like and respiratory problems till now, but recently the Centre for Disease Control and Prevention, the US agency charged with tracking and investigating public health trends, has come up with new symptoms of novel coronavirus. These new symptoms include symptoms like chills, repeated shaking with chills, headache, muscle pain, loss of taste and smell. Some experts say the new symptoms have been observed in Indian patients too while others have maintained that no such study in India has been published yet and it requires more evidence and data for this conclusion. Speaking to IANS, Senior Resident of Infectious Diseases department of All India Institute of Medical Sciences, New Delhi, Dr Soumyadip Chatterji said, "Yes, we are getting patients with these complaints." Dr Cahtterji explained that people having complaints of loss of smell feel very irritated. "Anosmia is very irritating for patients. Anosmia is loss of smell." Dr Chatterji, who is currently posted at AIIMS dedicated COVID centre in Jhajjar, Haryana, told IANS that such symptoms in Indian COVID patients were visible since the end of March. "As the number of patients increased here in India, we found these symptoms in Indian patients too. I recently encountered an aged diabetic who was unable to take food as he had loss of taste and smell," said Dr Chatterji.